Stadol "NDA Day"
Executive Summary
Agenda questions concerning nasal form of Bristol-Myers Squibb's butorphanol were not completed at June 24 meeting at FDA. Company and agency expect to meet again "within the month" to continue discussion. The company is seeking an indication for moderate to severe pain for nasal Stadol.